Skip to main content
. 2023 May 24;29(17):3418–3428. doi: 10.1158/1078-0432.CCR-23-0580

Figure 4.

Figure 4. Real-world survival estimates. A, OS for all patients treated with first-line platinum-containing chemotherapy regimens after metastatic index lung cancer diagnosis. B, PFS imaging-and-medical oncology (PFS I-and-M) for all patients treated with first-line platinum-containing chemotherapy. A total of 179 patients were excluded because of disease progression prior to sequencing test performed. C, OS for all patients treated with second-line or higher ICIs. D, PFS I-and-M for all patients treated with second-line or higher ICI E. OS for all patients treated with second-line or higher docetaxel-containing regimens. F, PFS I-and-M for all patients treated with second-line or higher docetaxel.

Real-world survival estimates. A, OS for all patients treated with first-line platinum-containing chemotherapy regimens after metastatic index lung cancer diagnosis. B, PFS imaging-and-medical oncology (PFS I-and-M) for all patients treated with first-line platinum-containing chemotherapy. A total of 179 patients were excluded because of disease progression prior to sequencing test performed. C, OS for all patients treated with second-line or higher ICIs. D, PFS I-and-M for all patients treated with second-line or higher ICI E. OS for all patients treated with second-line or higher docetaxel-containing regimens. F, PFS I-and-M for all patients treated with second-line or higher docetaxel.